Schizophrenia Drugs And Diabetes: VA Data On Causal Link Expected In June
Executive Summary
The Department of Veterans Affairs expects to have data from a study on the relationship between atypical antipsychotics and diabetes in late June
You may also be interested in...
VA Antipsychotic Diabetes Risk Studies Continue; First Report Helps Zyprexa
The Department of Veteran's Affairs plans to conduct a study on the incidence of diabetes among patients receiving combination antipsychotic therapy as a follow up to its study of patients on monotherapy
VA Antipsychotic Diabetes Risk Studies Continue; First Report Helps Zyprexa
The Department of Veteran's Affairs plans to conduct a study on the incidence of diabetes among patients receiving combination antipsychotic therapy as a follow up to its study of patients on monotherapy
VA study of antipsychotic-related diabetes
Department of Veteran's Affairs study "Antipsychotic Induced Diabetes in Veteran Schizophrenic Patients" will be submitted to the Journal of the American Medical Association for publication at the beginning of September (1"The Pink Sheet" April 21, 2003, p. 11). The study, scheduled to be presented at the International Conference on Therapeutic Risk in Philadelphia Aug. 24, found that Lilly's Zyprexa, Johnson & Johnson's Risperdal and AstraZeneca's Seroquel are associated with similar rates of metabolic complications...